Zevenbergen Capital Investments’s AbbVie ABBV Stock Holding History

Zevenbergen Capital Investments’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$484K	Hold	1,923	–	–	0.01%	100
2026 Q1	$418K	Hold	1,923	–	–	0.01%	103
2025 Q4	$439K	Hold	1,923	–	–	0.01%	99
2025 Q3	$445K	Hold	1,923	–	–	0.01%	96
2025 Q2	$357K	Hold	1,923	–	–	0.01%	98
2025 Q1	$403K	Hold	1,923	–	–	0.01%	99
2024 Q4	$342K	Hold	1,923	–	–	0.01%	98
2024 Q3	$380K	Hold	1,923	–	–	0.01%	94
2024 Q2	$330K	Hold	1,923	–	–	0.01%	98
2024 Q1	$350K	Hold	1,923	–	–	0.01%	96
2023 Q4	$298K	Hold	1,923	–	–	0.01%	95
2023 Q3	$287K	Hold	1,923	–	–	0.01%	97
2023 Q2	$259K	Hold	1,923	–	–	0.01%	100
2023 Q1	$306K	Hold	1,923	–	–	0.01%	97
2022 Q4	$311K	Hold	1,923	–	–	0.01%	94
2022 Q3	$258K	Hold	1,923	–	–	0.01%	100
2022 Q2	$295K	Hold	1,923	–	–	0.01%	82
2022 Q1	$312K	Hold	1,923	–	–	0.01%	82
2021 Q4	$260K	Buy	+1,923	New	+$227K	0.01%	88
2020 Q4	–	Sell	-2,567	Closed	-$225K	–	83
2020 Q3	$225K	Sell	2,567 -50	-2%	-$4.71K	﹤0.01%	80
2020 Q2	$257K	Sell	2,617 -150	-5%	-$13.2K	0.01%	80
2020 Q1	$211K	Hold	2,767	–	–	0.01%	79
2019 Q4	$245K	Sell	2,767 -70	-2%	-$5.81K	0.01%	82
2019 Q3	$215K	Buy	+2,837	New	+$195K	0.01%	80
2019 Q2	–	Sell	-2,712	Closed	-$219K	–	81
2019 Q1	$219K	Hold	2,712	–	–	0.01%	77
2018 Q4	$250K	Hold	2,712	–	–	0.01%	77
2018 Q3	$257K	Buy	2,712 +150	+6%	+$14.2K	0.01%	82
2018 Q2	$237K	Sell	2,562 -500	-16%	-$48.8K	0.01%	85
2018 Q1	$290K	Sell	3,062 -200	-6%	-$22K	0.01%	81
2017 Q4	$315K	Hold	3,262	–	–	0.01%	79
2017 Q3	$290K	Hold	3,262	–	–	0.01%	78
2017 Q2	$237K	Sell	3,262 -1,260	-28%	-$84.7K	0.01%	78
2017 Q1	$295K	Sell	4,522 -303	-6%	-$19.1K	0.01%	79
2016 Q4	$302K	Sell	4,825 -667	-12%	-$40.7K	0.01%	76
2016 Q3	$346K	Hold	5,492	–	–	0.01%	78
2016 Q2	$340K	Hold	5,492	–	–	0.02%	68
2016 Q1	$314K	Buy	+5,492	New	+$306K	0.01%	68

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Zevenbergen Capital Investments's ABBV Position: Q2 2026 in Review

Zevenbergen Capital Investments held its AbbVie (ABBV) position steady in Q2 2026 at 1,923 shares worth $484K. The position accounts for 0.01% of the portfolio, ranked #100.

Zevenbergen Capital Investments first reported a position in ABBV in Q1 2016 and has held it in 37 quarters since. 4,193 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Zevenbergen Capital Investments held 1,923 shares of AbbVie worth $484K as of Q2 2026.
Zevenbergen Capital Investments left its AbbVie share count unchanged in Q2 2026.
AbbVie made up 0.01% of Zevenbergen Capital Investments's portfolio in Q2 2026, its #100 holding.
Zevenbergen Capital Investments first reported a position in AbbVie in Q1 2016 and has held it in 37 quarters since.
4,193 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Zevenbergen Capital Investments's 13F filing for Q2 2026, filed 16 Jul 2026.